IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms
Open Access
- 26 May 2015
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 125 (7) , 2579-2591
Abstract
Myeloproliferative neoplasms (MPNs) are characterized by the clonal expansion of one or more myeloid cell lineage. In most cases, proliferation of the malignant clone is ascribed to defined genetic alterations. MPNs are also associated with aberrant expression and activity of multiple cytokines; however, the mechanisms by which these cytokines contribute to disease pathogenesis are poorly understood. Here, we reveal a non-redundant role for steady-state IL-33 in supporting dysregulated myelopoiesis in a murine model of MPN. Genetic ablation of the IL-33 signaling pathway was sufficient and necessary to restore normal hematopoiesis and abrogate MPN-like disease in animals lacking the inositol phosphatase SHIP. Stromal cell–derived IL-33 stimulated the secretion of cytokines and growth factors by myeloid and non-hematopoietic cells of the BM, resulting in myeloproliferation in SHIP-deficient animals. Additionally, in the transgenic JAK2V617F model, the onset of MPN was delayed in animals lacking IL-33 in radio-resistant cells. In human BM, we detected increased numbers of IL-33–expressing cells, specifically in biopsies from MPN patients. Exogenous IL-33 promoted cytokine production and colony formation by primary CD34+ MPN stem/progenitor cells from patients. Moreover, IL-33 improved the survival of JAK2V617F-positive cell lines. Together, these data indicate a central role for IL-33 signaling in the pathogenesis of MPNs.Keywords
This publication has 49 references indexed in Scilit:
- Long-term IL-33–producing epithelial progenitor cells in chronic obstructive lung diseaseJournal of Clinical Investigation, 2013
- MyD88 is critically involved in immune tolerance breakdown at environmental interfaces of Foxp3-deficient miceJournal of Clinical Investigation, 2012
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia DevelopmentCancer Cell, 2011
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activityJournal of Clinical Investigation, 2011
- IL-33 is a crucial amplifier of innate rather than acquired immunityProceedings of the National Academy of Sciences, 2010
- Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritisProceedings of the National Academy of Sciences, 2010
- Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokinesBlood, 2009
- Risks of myeloid malignancies in patients with autoimmune conditionsBritish Journal of Cancer, 2009
- Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial triggerProceedings of the National Academy of Sciences, 2008
- Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5Journal of Clinical Investigation, 2008